Skip to main content
. Author manuscript; available in PMC: 2009 May 15.
Published in final edited form as: Clin Cancer Res. 2008 May 15;14(10):2900–2908. doi: 10.1158/1078-0432.CCR-07-1719

Fig 5.

Fig 5

Pattern of ex vivo PARP inhibition observed in PBLs from patient treated with a PARP inhibitory dose of AG-014699 27.8 mg (12 mg/m2). Abbreviations: PAR, poly(ADP)-ribose; PBL, peripheral blood lymphocytes.